about3.jpg

Immunopheresis™

Immunopheresis is an investigational therapy that has not been approved by the FDA for any use. In addition to the planned clinical evaluation of Immunopheresis at Sheba Medical Center to treat several cancers, Immunopheresis is currently being evaluated to treat triple-negative breast cancer (TNBC) in an ongoing clinical trial being conducted in Poland. It is not yet known if Immunopheresis is safe and effective for the treatment of any of these or other cancers.

6048 CORNERSTONE COURT W

SUITE D, 

SAN DIEGO, CA 92121

General Inquiries

business@immunicom.com

(657) 202-6388

Media Relations

publicrelations@immunicom.com

(657) 202-6040

©2018 Immunicom, Inc. All rights reserved.

  • Black LinkedIn Icon